These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15140545)

  • 1. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
    Cheran SK; Herndon JE; Patz EF
    Lung Cancer; 2004 Jun; 44(3):317-25. PubMed ID: 15140545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
    Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
    Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging non-small cell lung cancer with whole-body PET.
    Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
    Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy comparison between (18)F-FDG PET/CT and bone scintigraphy in detecting bony metastases of non-small-cell lung cancer.
    Song JW; Oh YM; Shim TS; Kim WS; Ryu JS; Choi CM
    Lung Cancer; 2009 Sep; 65(3):333-8. PubMed ID: 19144446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
    Ak I; Sivrikoz MC; Entok E; Vardareli E
    Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of whole-body FDG PET/CT, Tc 99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer.
    Min JW; Um SW; Yim JJ; Yoo CG; Han SK; Shim YS; Kim YW
    J Korean Med Sci; 2009 Apr; 24(2):275-80. PubMed ID: 19399270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL; Fischman AJ
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.
    Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K
    J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer.
    Gayed I; Vu T; Johnson M; Macapinlac H; Podoloff D
    Mol Imaging Biol; 2003; 5(1):26-31. PubMed ID: 14499159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET).
    Kut V; Spies W; Spies S; Gooding W; Argiris A
    Am J Clin Oncol; 2007 Feb; 30(1):45-50. PubMed ID: 17278894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
    Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S
    Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA; McAdams HP; Herndon JE; Patz EF
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of bone scintigraphy and (18)F-FDG PET/CT in bone metastases of lung cancer patients].
    Portilla-Quattrociocchi H; Banzo I; Martínez-Rodríguez I; Quirce R; Jiménez-Bonilla J; de Arcocha Torres M; Medina-Quiroz P; del Castillo R; Rubio-Vassallo A; Carril JM
    Rev Esp Med Nucl; 2011; 30(1):2-7. PubMed ID: 21208693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic performance of [18F] FDG PET-CT compared to bone scintigraphy for the detection of bone metastases in lung cancer patients.
    Rodrigues M; Stark H; Rendl G; Rettenbacher L; Datz L; Studnicka M; Pirich C
    Q J Nucl Med Mol Imaging; 2016 Mar; 60(1):62-8. PubMed ID: 26844431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and patterns of bone metastases detected with positron emission tomography using F-18 FDG.
    Nakamoto Y; Osman M; Wahl RL
    Clin Nucl Med; 2003 Apr; 28(4):302-7. PubMed ID: 12642709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer.
    Sazon DA; Santiago SM; Soo Hoo GW; Khonsary A; Brown C; Mandelkern M; Blahd W; Williams AJ
    Am J Respir Crit Care Med; 1996 Jan; 153(1):417-21. PubMed ID: 8542152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer.
    Ito S; Kato K; Ikeda M; Iwano S; Makino N; Tadokoro M; Abe S; Nakano S; Nishino M; Ishigaki T; Naganawa S
    J Nucl Med; 2007 Jun; 48(6):889-95. PubMed ID: 17504877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy.
    Ohta M; Tokuda Y; Suzuki Y; Kubota M; Makuuchi H; Tajima T; Nasu S; Suzuki Y; Yasuda S; Shohtsu A
    Nucl Med Commun; 2001 Aug; 22(8):875-9. PubMed ID: 11473206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.